Skip to main content
. 2019 Nov 19;28(1):3–13. doi: 10.1007/s12471-019-01342-8

Fig. 4.

Fig. 4

Differences between the United States and the Netherlands in the use of (a) and dosing of (b) guideline-recommended medication in patients with heart failure and reduced ejection fraction in the CHAMP-HF [43] and CHECK-HF [44] registries. MRA mineralocorticoid receptor antagonist (Adapted from [43, 44], with permission)